Here we describe rapid neurotoxicity in mice and cerebellar organotypic cultured slices exposed to ligands targeting the a1 and a3 helices of the PrP C globular domain. Ligands included seven distinct monoclonal antibodies 3 , monovalent Fab 1 fragments and recombinant singlechain variable fragment miniantibodies. Similar to prion infections [4] [5] [6] , the toxicity of globular domain ligands required neuronal PrP C , was exacerbated by PrP C overexpression, was associated with calpain activation and was antagonized by calpain inhibitors. Neurodegeneration was accompanied by a burst of reactive oxygen species, and was suppressed by antioxidants. Furthermore, genetic ablation of the superoxide-producing enzyme NOX2 (also known as CYBB) protected mice from globular domain ligand toxicity. We also found that neurotoxicity was prevented by deletions of the octapeptide repeats within the flexible tail. These deletions did not appreciably compromise globular domain antibody binding, suggesting that the flexible tail is required to transmit toxic signals that originate from the globular domain and trigger oxidative stress and calpain activation. Supporting this view, various octapeptide ligands were not only innocuous to both cerebellar organotypic cultured slices and mice, but also prevented the toxicity of globular domain ligands while not interfering with their binding. We conclude that PrP C consists of two functionally distinct modules, with the globular domain and the flexible tail exerting regulatory and executive functions, respectively. Octapeptide ligands also prolonged the life of mice expressing the toxic PrP C mutant 7 , PrP(D94-134), indicating that the flexible tail mediates toxicity in two distinct PrP C -related conditions. Flexible tail-mediated toxicity may conceivably play a role in further prion pathologies, such as familial Creutzfeldt-Jakob disease in humans bearing supernumerary octapeptides.
The infectious prion PrP Sc , which causes transmissible spongiform encephalopathies, is a pathologically misfolded conformational variant of PrP C , a glycosylphosphatidyl-inositol (GPI) linked cell-surface protein encoded by the Prnp locus 8 . Only PrP C -expressing cells are damaged by prion infections 1 , suggesting that neurotoxicity is triggered by PrP C -PrP Sc interactions on cell membranes. In an effort to model such interactions, we exposed cerebellar organotypic cultured slices (COCS) 4, 9 to a panel of anti-PrP antibodies directed against well-defined PrP C epitopes 3 . Supplementary Fig. 1 summarizes our main findings and Supplementary Table 1 lists all abbreviations. PrP C -overexpressing COCS (derived from tga20 mice that are hypersensitive to prion diseases 5 ) were treated with 5 antibodies against the flexible tail (FT) of PrP C (residues 23-123) (ref. 10 ) and with 12 antibodies against the globular domain (GD) of PrP C (residues 124-230; Supplementary Table 2; Fig. 1a) . Seven of the antibodies targeting the GD induced dramatic loss of cerebellar granule cells (CGC) at 67 nM and one was toxic at 333 nM, whereas four were innocuous (Fig. 1b) . None of three high-affinity antibodies to the octapeptide repeats (OR, residues 50-90 embedded within the FT) were neurotoxic (Fig. 1b) . Antibodies POM3 and D13, which bind the 'charged cluster-2' (ref. 11) (CC2, residues 95-110 of the FT), were innocuous at 67 nM but neurotoxic at 200 nM (Fig. 1b) . None of the tested antibodies were toxic to Prnp o/o COCS ( Supplementary Fig. 2a ). The identity of the targeted epitopes appeared to be a better predictor of PrP C antibody binding induced toxicity than their affinity to PrP C , suggesting that neurotoxicity resulted from the interaction of antibodies with specific PrP C domains (Supplementary Table 2 ).
The mechanisms of neurotoxicity were further explored using POM1, a highly toxic antibody targeting the GD. Wild-type and tga20 COCS lost most granule cells (CGC) within 28 and 14 days post-exposure (dpe) to POM1, respectively (Fig. 2a-c) .
, tga20 COCS treated with pooled mouse immunoglobulins (IgG) and tga20 COCS treated with POM1 preincubated with full-length recombinant mouse PrP (PrP ). All of these controls were unaffected (Fig. 2d) , indicating that POM1 toxicity was PrP C -dependent. Propidium iodide (PI) staining, a marker of cell death, revealed that CGC membrane integrity was compromised before overt neuronal loss in POM1-treated tga20 COCS. The prevalence of PI 1 cells peaked at 3-5 days and decreased thereafter, suggesting removal of dead cells (Fig. 2e, Supplementary Fig. 3 ). Therefore POM1-mediated neurotoxicity was dependent on Prnp gene dosage as well as duration and dosage of the antibody treatment. Similarly to neurotoxicity in prion infections 6 , neuronal PrP C expression was necessary and sufficient for POM1 toxicity ( Supplementary Fig. 4a-c) , suggesting that its effects were cell-autonomous to neurons. Finally, treatment of COCS with an anti-NOGO (also known as RTN4) receptor antibody was innocuous, indicating that toxicity was not a generic consequence of binding to GPI-linked receptors ( Supplementary Fig. 4d ).
It was previously reported that antibody-mediated crosslinking of PrP C at the cell surface leads to neurotoxicity 11 . However, both monovalent and divalent POM1, POM17 and POM19 derivatives (Fab 1 fragments, Fab 2 fragments and recombinant single-chain variable fragment (scFv) miniantibodies) induced neurotoxicity in tga20 COCS but not in Prnp o/o COCS (Fig. 2f , g and Supplementary Figs 2b and 5). Hence neurotoxicity was rapidly induced by structurally diverse GD ligands, and did not require antibody effector functions mediated by Fc receptors (Fig. 2f, g ) or complement ( Supplementary Fig. 6 ).
Neurotoxicity may result from conformational changes imposed onto PrP C by POM1. We therefore solved the crystal structure of the protein complex containing POM1 Fab 1 bound to recombinant mouse PrP residues 120-230, (PrP(120-230)) (Supplementary Fig. 7 ; Supplementary  Tables 2 and 3 ). The POM1 epitope on PrP(120-230) was discontinuous and included the C-terminal part of the b1-a1 loop, the N-terminal part of helix a1, as well as a segment of helix a3. The surface area of the interface was around 580 Å 2 and involved primarily the POM1 heavy chain (Supplementary Video 1 and Supplementary Fig. 7 ). Comparisons with published structures 2, 10, 13, 14 indicate that Fab 1 POM1 binding did not cause conformational distortions in the GD. We also studied the binding interface of scFv POM1 complexed with PrP(23-230) by solution nuclear magnetic resonance (NMR) spectroscopy. Overlays of the NMR spectra of PrP(23-230) with those of the scFv POM1 -PrP(23-230) complex did not reveal appreciable perturbations of the FT (Supplementary Fig. 8 ), whereas PrP C residues in contact with scFv POM1 in the GD displayed chemical shift changes as expected from the crystal structure. Moreover, we found subtle perturbations in the chemical shifts in the b1/b2 regions that were not present in the crystal structure ( Supplementary Fig. 8 ).
To investigate whether the FT contributes to the neurotoxicity of GD ligands, we administered POM1 to COCS expressing either PrP(D32-93) (lacking most of the FT) or PrP(D94-110) (lacking the CC2) 15, 16 (Supplementary 9a). Although PrP(D94-110) COCS experienced POM1-dependent neurodegeneration, COCS overexpressing PrP(D32-93) were resistant to all tested neurotoxic antibodies, POM1, POM4, POM8 and POM19 (Fig. 3a, Supplementary Figs 4b and 9b, c) . The affinities of POM1 Fab 1 fragments for N-terminally truncated prion protein PrP(90-230) and full-length recombinant PrP(23-230) were similar (2.9 and 2.5 nM, respectively; Supplementary Table 2 ), confirming that the resistance of PrP(D32-93) COCS to POM1 effect was not due to any steric changes compromising the POM1 binding site.
These results suggested that the FT is required for GD ligandmediated toxicity. If so, engaging the FT with antibodies might prevent the toxicity of GD antibodies. Indeed, preincubation of tga20 COCS with OR antibodies (POM2 or POM11), or with scFv derivatives, blocked POM1 toxicity (Fig. 3b, c) . Interestingly, low concentrations of POM3 and D13 also blocked POM1 toxicity, although these antibodies were toxic at higher concentrations (Fig. 3b) . Hence antibodies binding One-way ANOVA with Tukey's post-hoc test. e, COCS were treated with POM1 (67 nM) and scored for NeuN 1 (blue) and PI 1 (red) area coverage within the cerebellar granular layer. PI incorporation peaked at 3 dpe, coinciding with the maximum slope of NeuN decay. f, Prnp o/o and tga20 COCS were incubated with POM1 holoantibody, divalent Fab 2 , monovalent Fab 1 , or scFv derivatives of POM1. NeuN morphometry identified severe neurodegeneration after exposure (10 dpe) to each ligand irrespective of its valence. Red dashed lines (here and elsewhere) delineate independent experiments normalized against their respective IgG control assays. One-way ANOVA with Dunnett's post-hoc test. g, Treatment of tga20 COCS for 21 days with Fab 1 fragments of POM17 and POM19 (134 nM) resulted in similar toxicity as with holoantibodies, whereas Fab 1 POM5 and Fab 1 POM15 were innocuous. One-way ANOVA with Tukey's post-hoc test. For all experiments, data in bar charts are presented as mean 6 s.d., n 5 9 biological replicates; ***P , 0.001. NS, not significant.
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the CC2 acted similarly to pharmacological 'partial antagonists', triggering opposite effects depending on the presence or absence of additional ligands. Crucially, neither POM2 nor POM3 sterically hinders POM1 binding 3, 4 and the non-toxic GD antibody POM5, which did not compete for the POM1 epitope 3 ( Supplementary Fig. 9d ) did not rescue neurotoxicity ( Supplementary Fig. 9e ). We conclude that the domain executing toxicity resides within the FT.
Although we suspected that POM1 treatment would result in apoptosis, electron micrographs of POM1-treated COCS revealed cell death with morphology distinct from typical apoptosis ( Supplementary Fig. 10 ). Furthermore, POM1 did not induce caspase activity (Fig. 3e) , and the caspase antagonist zVAD conferred no neuroprotection against POM1 (Fig. 3d) . Instead, proteolysis of the calpain substrates, a-fodrin 17 and Ac-LLY-AFC, was significantly raised after scFv POM1 and POM1 treatment (Fig. 3e, f) , and calpain inhibition prevented POM1-mediated toxicity (Fig. 3d) . None of the compounds used in the above experiments affected the viability of IgG-treated COCS ( Supplementary Fig. 11a ). Hence POM1 neurotoxicity results in calpain-dependent cell death, similar to cell death in prion-infected COCS 4 . Oxidative stress is a common promoter of neurodegeneration 18 , raising the question of its possible involvement in the toxicity of GD ligands. Indeed, the reactive oxygen species (ROS) scavengers, ascorbate (0.1-2.5 mM) and N-acetyl cysteine (NAc), conferred neuroprotection against POM1-mediated toxicity (Fig. 3d, Supplementary Fig. 11a, b) . Longterm incubation of POM1 with ascorbate did not reduce the binding of POM1 to PrP(23-230), ruling out the possibility that antioxidants affected antibody stability ( Supplementary Fig. 11c ). The cell-impermeable molecule isoascorbate was also protective, suggesting that the relevant ROS were extracellular (Fig. 3d, Supplementary 11a ). Moreover, inhibition of nitric oxide production did not show a protective effect, whereas the superoxide dismutase mimetic MnTBAP abolished POM1 neurotoxicity ( Fig. 3d and Supplementary Fig. 11a ), pointing to superoxide rather than nitric oxide as the critical ROS species. NADPH oxidases (NOX) are an important source of extracellular superoxide 19 , and indeed scFv POM1 treatment induced a superoxide spike in COCS that was suppressed by the NOX inhibitor, diphenyleneiodonium chloride (DPI; Fig. 3g ). Hence GD ligands initiate a cascade of events which ultimately triggers the activation of NADPH oxidases.
We then investigated the effects of GD ligands in intact mice. POM1 or IgG were stereotactically injected into the cerebella of tga20 and Prnp o/o mice ( Fig. 4a, Supplementary Fig. 12a ). Sequential manganeseenhanced magnetic resonance imaging (MEMRI) 20 revealed hypointense (dark) lesions indicative of oedema formation arising at 4-72 h post-injection. At their peak, such lesions occupied up to 2.5% and 20% of the total cerebellar volume of wild-type and tga20 mice, respectively (Fig. 4a, b and Supplementary Fig. 12b ). Histology revealed CGC chromatin condensation beginning at 5 h post-injection ( Supplementary  Fig. 13a ), conspicuous tissue oedema by 24 h (Supplementary Fig. 13b ), and pyknotic CGC death with limited perifocal haemorrhages by 72 h (Fig. 4a) . After one week, we found substantial neuronal loss and glial scars ( Supplementary Fig. 13c ). No such changes were observed in IgGtreated tga20 or POM1-treated Prnp o/o mice ( Fig. 4a , b, and Supplementary Fig. 13 ). Hypointense lesions also arose after stereotactic injection of POM1 or D13 into tga20 hippocampi, histologically identified as sites of extensive degeneration of CA3 and dentate gyrus neurons ( Supplementary Fig. 14) . Intracerebellar injection of scFv POM1 also induced extensive lesions in tga20 cerebella and smaller lesions in wildtype cerebella (Fig. 4c ). Lesions did not arise when scFv POM1 was preincubated with PrP(23-230), and when scFv POM1 was administered to Prnp o/o mice (Fig. 4c) . ScFv POM2 was innocuous to tga20 mice (Fig. 4c ). Hence these in vivo results confirm that toxicity was dependent on GD binding and on PrP C expression levels, but neither on antigen crosslinking nor on any antibody effector functions. As with COCS, neuronrestricted PrP C expression sufficed to confer scFv POM1 susceptibility in vivo (Fig. 4d) , whereas mice expressing PrP(D32-93) 15 were resistant to scFv POM1 toxicity despite higher PrP(D32-93) expression, PrP(D94-110) mice 16 lacking only the CC2 domain of PrP C experienced toxicity ( Mice expressing PrP(D94-134), which lacks the central domain that connects the FT and the GD of PrP C , develop spontaneous neurodegeneration whose pathogenesis is poorly understood 7 ( Supplementary  Fig. 9a ). If this pathology were mediated by the FT, it might be alleviated by anti-FT antibodies. Indeed, a single intraventricular injection One-way ANOVA with Dunnett's post-hoc test. e, Cultures (3 dpe) were assayed for DEVDase (black) and LLYase activity (red), indicative of caspase and calpain activity, respectively. Although staurosporine (24 h) increased both activities, POM1 treatment increased LLYase but not DEVDase activity. Protease activity was normalized to protein amount 6 s.d. One-way-ANOVA with Dunnett's post-test, mean 6 s.d., n 5 3 pools of 18 slices. f, Immunodetection of a-fodrin in tga20 COCS (3 dpe). ScFv POM1 treatment increased total a-fodrin cleavage and the calpain-specific fragment of 145 kDa (n 5 3 pools of 6 slices; mean 6 s.d. underneath blot; two-tailed Student's t-test, P 5 0.0054). g, ScFv
POM1
-treated COCS (400 nM, 24h) were collected and analysed for ROS production by lucigenin assay in the presence or absence of DPI. One-way ANOVA with Dunnett's post-hoc test, mean 6 s.d., n 5 4, each data point represents a pool of 9 slices. For all experiments, data in bar charts are presented as mean 6 s.d., n 5 9 biological replicates; ***P , 0.001, **P , 0.01.
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of POM2 to newborn (P0) PrP(D94-134) mice resulted in significantly increased median survival (26 vs. 22 days, n 5 9; Fig. 4f ), suggesting that the FT is also involved in the neurotoxicity of these PrP C mutants. To determine whether ROS are involved in POM1 neurotoxicity in vivo, we administered the enterically activated antioxidant, acetylated hydroxytyrosol 21 (AcHyt) to tga20 mice. Five of six untreated, but only one of six AcHyt-treated tga20 mice developed cerebellar lesions upon scFv POM1 injection ( Fig. 4g; Supplementary Fig. 15 ). POM1-treated NADPH oxidase 2 (NOX2) deficient mice 22 displayed much smaller lesions than POM1-treated wild-type controls (Fig. 4h) , implicating NOX2 as the crucial source of ROS in this model. The data reported above uncover a critical role for the FT as the effector domain of PrP C -mediated neuronal death. FT-mediated toxicity appears to arise from inappropriate gain of deleterious functions, rather than loss of homeostatic interactions, because shortening or steric masking of the FT conferred protection from neurotoxicity (Supplementary Fig. 1a, b) , and because most Prnp transgenes bearing interstitial FT deletions 5, 15, 23 are innocuous. Similar mechanisms may be operative in mice 24 and humans [25] [26] [27] expressing PrP C variants with supernumerary OR (Supplementary Fig. 1c ). These syndromes are surprising because the OR lie outside the PrP Sc amyloid core and are dispensable for prion generation 15, 23 . If the disease caused by supernumerary OR is mechanistically equivalent to that elicited by GD ligands, agents effective against GD ligand toxicity may also be beneficial to patients with OR insertions.
Might GD ligands be toxic by emulating the docking of PrP
Sc to PrP C ? This conjecture is supported by the role of activated calpains, which are involved in mediating the neurodegeneration occurring in prion infections. Perhaps PrP Sc oligomers engage PrP C through its a1/ a3 helices in a similar way to the GD ligands ( Supplementary Fig. 1c ). In this scenario soluble PrP C may reduce prion toxicity 28 by intercepting PrP Sc oligomers and preventing them from interacting with membrane-bound PrP C . Furthermore, the dramatic effects of GD ligands in vivo suggest that anti-GD autoimmunity may cause neurological conditions, and that it may be worthwhile screening patients with idiopathic neurodegeneration for such autoantibodies.
METHODS SUMMARY
Slices were prepared using a vibratome from 10-12-day-old mice according to a previously published protocol 9 . Viability was assessed by quantifying propidium iodide incorporation or NeuN immunoreactive area using analysis software analySIS v.5.0 (Olympus BioSystem). Fab 1 and Fab 2 fragments were generated by ficin digestion, isolated after protein A elution and further purified by size exclusion chromatography. Single chain fragments of POM1 and POM2 were expressed in Escherichia coli (periplasm) and purified by Ni-NTA agarose columns. Recombinant mouse prion proteins (23-230 and 90-230) were generated in bacteria and purified as reported 29, 30 . The POM1 epitope was determined by X-ray and NMR analyses as described in the Methods section. Antibodies and respective fragments were stereotactically injected into mouse brains; lesions were visualized by MEMRI and quantified with ParaVision software (v.5 Opl3, Bruker). Surface 
d., two-tailed Student's t-test). d, MEMRI volumetry (24 h post intracerebellar injection) of neuron-specific enolase (NSE, also known as Eno2) NSE-PrP (NSE promoter driving specifically neuronal PrP expression) (n 5 4) and Prnp
o/o (n 5 7) mice injected with scFv POM1 (3 mg; mean 6 s.d., two-tailed Student's t-test). e, MEMRI volumetry 24 h post intracerebellar injection of scFv POM1 injected into PrP(D94-110) (L52, n 5 3) , PrP(D32-93) (n 5 5) and wild type (n 5 8) (mean 6 s.d.; two-tailed Student's t-test). f, Survival of mice expressing a PrP(D94-134) transgene was prolonged by intraventricular POM2 (n 5 9) treatment versus IgG control (n 5 5) (4 mg, Mantel-Cox test). g, tga20 mice 24 h post intracerebellar injection of scFv POM1 (2 mg) and pre-treated with AcHyt (mean 6 s.d., n 5 6, one-tailed student t-test. P 5 0.013). h, MEMRI volumetry at 24 h post intracerebellar injection of scFv POM1 (3 mg) injected into Prnp o/o (n 5 7), wild-type (n 5 5) and NOX2-deficient (n 5 11) mice (mean 6 s.d., one-tailed Student's t-test).
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plasmon resonance experiments were performed with a BIAcore X100 instrument and interpreted with BIAcore T100 Evaluation Software, v.2.0.3. and the Novartis Research Foundation. J. Author Information X-ray crystallographic coordinates and structure factor files have been deposited in the RSCB Protein Data Bank (PDB) database under the accession code number 4H88. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to A.A. (Adriano.Aguzzi@usz.ch).
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Chemicals and mice. All compounds were purchased from Sigma-Aldrich unless otherwise stated. GABA-Aa6-Cre mice were generated on a C57BL/6 3CBA background and backcrossed to a Prnp o/o background 12, 31 . Tg37 mice allowing for conditional PrP deletion were generated on a Animal surgery. Mice were anaesthetized with isoflurane and placed in a motorized stereotaxic frame controlled by software with a three-dimensional brain map, allowing for real-time monitoring of needle placement (Neurostar). The skull was exposed by cutting along the midline and a small hole was drilled using a surgical drill and the needle mounted in an electronic micro-injector unit was placed for cerebellar injection at the following lambda coordinates: AP 22.3 mm, ML 0 mm, DV 2 mm and for hippocampal injection at the following bregma coordinates: AP 22 mm, ML 1.7 mm, DV 2.2 mm, angle in ML/DV plane 15u. Antibodies (2 ml) were injected at a flow-rate of 0.5 ml min 21 and the needle was left in place for 1 min. Mice were sutured and received an injection of buprenorphinum (0.1 mg per g of body weight). Hydroxytyrosol treatment. Mice were treated with acetylated hydroxytyrosol starting 7 days before injection with 2g l 21 in drinking water. Newborn injections. Newborn mice (P0) were injected with a thin Hamilton syringe into the lateral ventricle (2 ml of 2 mg ml 21 IgG or POM2 solution into each hemisphere) according to previously reported protocols 36 .
Manganese-enhanced magnetic resonance imaging (MEMRI). Mice received five intraperitoneal injections of MnCl 2 (40 mg kg

21
, 20 mM in H 2 O and bicine, pH 7.4) at 12 h intervals 37 . The last injection was administered immediately after the stereotaxic injection. Mice were imaged under isoflurane anaesthesia at 4 h, 24 h and 72 h post-surgery in a 4.7-Tesla small-animal MRI system (Bruker Pharmascan). Mice were placed in a bed equipped with a mouse whole-body radio frequency transmitter coil and a mouse head surface-coil receiver (Bruker Pharmascan). Body temperature was maintained with a warming blanket. T-1 weighted brain images were obtained using a 3D gradient-echo sequence (TR: 15 Quantification was performed with ParaVision software (Version 5, Opl3, Bruker). Cerebellar lesions were quantified by two region of interests (ROIs) corresponding to the lesioned and total cerebellar area were set for each optical slice of the 3D data set. For hippocampal lesion quantification, the volume of non-affected CA3 was measured. ROIs were set on the ipsilateral and contralateral side of injection. Volumes for each ROI were calculated by multiplying the sum of the ROI area times the voxel height. Data are presented as the lesion volume divided by the total cerebellar volume, that is, lesion volume (%) or as CA3 volume (mm ) supplemented with the glutamate receptor antagonist kynurenic acid (1 mM) (GBSSK) at 4 uC. Slices were placed on a 6-well Millicell-CM Biopore PTFE membrane insert (Millipore). Residual buffer was removed and the inserts were transferred to a cell culture plate and cultured in 'slice-culture medium' (50% vol/vol MEM, 25% vol/vol basal medium Eagle and 25% vol/vol horse serum supplemented with 0.65% glucose (w/vol), penicillin/streptomycin and glutamax (Invitrogen)). Cultures were kept in a standard cell incubator (37 uC, 5% CO 2 , 95% humidity) and the culture medium was exchanged three times per week.
Antibody treatment was randomly assigned to individual wells and initiated after a 10-14-day recovery period allowing the initial gliosis induced by tissue preparation to subside. Slices were collected for biochemical analyses or fixed for immunocytochemical analysis at various time points. For microglia depletion experiments, tga20
TK1 slices were treated with ganciclovir (GCV, 5 mg ml
) for 14 days before antibody treatment. At this time point, less than 1% of microglia were left in the tissue 39 . Pharmacological treatment of COCS. Drug treatment was initiated at the time of antibody addition and drugs were added again at every medium change. Appropriate drug concentrations were determined by literature search, assuming that slice culture uptake of compounds were similar to other cell culture systems. The toxicity of each compound was tested in parallel on IgG and POM1 slices; if toxicity occurred, drugs were retested at a lower concentration. Drug and concentration used were ascorbate (1.5 mM), isoascorbate (1.5 mM), MnTBAP (100 mM), benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (zVAD-fmk, 40 mM), diphenyleneiodonium chloride (DPI, 5 mM), N-([3-(Aminomethyl)phenyl]methyl)-ethanimidamide dihydrochloride (1400W, 20 mM) , N-benzyloxycarbonyl-Lleucylnorleucinal (calpeptin, 20 mM), N-acetylcysteine (NaC, 1 mM) . Protein analysis. COCS were washed twice in PBS. Cerebellar tissue was then scraped off the membrane using 10 ml per slice of PBS with 0.5% DOC, 0.5% NP-40 supplemented with PMSF (1 mM) and complete mini protease inhibitor cocktail (Roche) and homogenized by trituration using a 30G syringe. Protein concentration was determined using the bicinchoninic acid assay (Pierce). Samples were prepared in loading buffer (NuPAGE, Invitrogen) and boiled at 95 uC for 5 min. Proteins (10 mg per lane) were separated on a 12% Bis-Tris polyacrylamide gel or for higher molecular weight proteins on a 4-12% gradient gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose membrane. Membranes were blocked with 5% w/vol Topblock (Fluka) in Tris-buffered saline supplemented with Tween (150 mM NaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol)) and incubated with primary antibodies in 1% Topblock. Primary mouse monoclonal antibodies used were: POM1, POM2, mouse IgG 1 antibody raised against PrP C (anti-PrP C ; 200 ng ml 21 ), mouse anti-a-fodrin (AA6, 100 ng ml
, Millipore) and anti-GAPDH (200 ng ml 21 , Millipore). Secondary antibodies were horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG 1 (1:10,000, Zymed), goat anti-rabbit IgG 1 (1:10,000, Zymed) and rabbit anti-goat IgG 1 (1:10,000, Zymed). Blots were developed using SuperSignal West Pico chemiluminescent substrate (Pierce) and visualized using the VersaDoc system (model 3000, Bio-Rad). PNGase treatment was performed using a commercially available kit, according to the manufacturer's protocol (New England Biolabs). In brief, 10 mg protein was treated with 2 ml denaturation buffer in a 20 ml reaction and incubated for 15 min at 95 uC. A reaction mixture of 2.6 ml G7, 2.6 ml NP-40 (10%), as well as 0.5 ml PNGase was added and samples were incubated for 2 h at 37 uC. Samples were then mixed with loading dye, cooked and analysed by western blotting. Cerebella from 10-day-old mice were homogenized (10% w/v) in 0.32 M sucrose in 13 PBS supplemented with 4-(2-Aminoethyl)-Benzene sulfonyl fluoride HCL (AEBSF, 1 mM) and complete mini protease inhibitor cocktail (Roche) using a tissue Ribolyser (Qiagen). PrP C expression in the brains of PrP deletion mutants was analysed by PrP-specific sandwich ELISA 3 . Briefly, samples were incubated in POM1-coated ELISA plates (overnight at 4 uC). Plates were then washed and incubated with biotinylated POM19 (1.6 ng ml
) for 1 h at 37 uC. Avidin-HRP (1:1,000) (BD-Pharmigen) was used as detection antibody (1 h, 37 uC). After 3 washes, stabilized chromogen (Invitrogen) was added, incubated for 30 min at 37uC and absorbance was read at 450 nM. All samples were analysed at dilutions falling within the logarithmic range of the calibration curve (PrP(23-230): 0.62-80 ng ml 21 ). Generation of POM monoclonals, Fab 1 POM1 and Fab 2 POM1 fragments. POM monoclonal antibodies were generated as published 3 . Fab 1 POM1 and Fab 2 POM1 fragments were generated by ficin digestion and purified on a protein A column according to manufacturer's protocol (Pierce). Protein A flow-through containing Fab 1 POM1 was collected, concentrated by Amicon ultra-15 centrifugal units (Millipore). Fab 1 POM1 was further purified by size exclusion chromatography (Superdex75 10/300 GL, GE Healthcare) using PBS and a flow rate of 0.5 ml min
. Pure fractions were pooled, concentrated and stored at 220 uC. The concentrations of the IgG and Fab 1 POM fragments were determined by measuring their absorbance at 280 nM in a UV-VIS photometer using an extinction coefficient (E) 0.1% at 280 nM of 1.35. Aldolase (158 kDa), conalbumin (75 kDa) and ovalbumin (43 kDa) were used as control molecular weight markers. The purity of the fragments was checked by Coomassie-stained SDS-PAGE.
For K d determination, Fab 1 POM fragments were generated from the POM antibodies using immobilized papain (10-20 mg of antibody ml 21 of immobilized papain as packed resin) activated in digestion buffer (20 mM sodium phosphate, 10 mM EDTA, 20 mM cysteine hydrochloride, pH 7.0) according to the manufacturer's instructions (Pierce). The reaction mixture was incubated overnight with rigorous shaking at 37 uC. The digest was separated from the immobilized papain with a resin separator. The immobilized papain was then washed with binding buffer (Protein A IgG binding buffer, Pierce) which was added to the digest.
To remove undigested IgG and Fc fragments from the Fab 1 fragments, the digest was loaded onto a 2 ml Protein A plus agarose column (Pierce), equilibrated in binding buffer and washed with 6 ml binding buffer. The Fab 1 -containing flow-through LETTER RESEARCH and wash fractions were pooled and further purified by size exclusion chromatography as described above. Periplasmic expression and purification of scFvPOM1, scFvPOM2, PrP and PrP(90-230). For periplasmic expression and purification of scFv POM2 , the pET-22b(1) vector (Novagen) was used, as it has both periplasmic localization and C-term 63His tag sequences. The scFvPOM2 gene, constructed previously using the phage display method 3 , was inserted into the pET-22b(1) vector between the restriction sites EcoRI and XhoI. The resulting plasmid was transformed into competent Rosetta (DE3) pLysS cells by heat-shock.
A fresh, single colony of transformed Rosetta cells was inoculated in 23YT media with 100 mg ml 21 ampicillin and 34 mg ml 21 chloramphenicol (23YT-AC media) and grown overnight at 37 uC at 250 r.p.m. The overnight culture was further propagated ( The clarified soluble protein extract was loaded onto a Ni-NTA agarose (Qiagen) column equilibrated with 50 mM Tris and 100 mM NaCl, pH 7.0. The unbound protein and impurities were washed off with 50 mM Tris, 100 mM NaCl and 50 mM imidazole pH 7.0 and the elution was performed with 50 mM Tris, 100 mM NaCl and 500 mM Imidazole pH 7.0. The purity of the eluates was checked using gel electrophoresis. Pure scFv POM2 samples were dialysed against 50 mM Tris, 100 mM NaCl and 50 mM Imidazole pH 7.0 and concentrated to ,3 mg ml 21 . The same procedures applied to expression and purification of periplasmic scFv POM1 except the induction was at 17 uC. Recombinant mouse PrP was generated in bacteria and purified as reported elsewhere 29, 30 . SPR measurements and binding affinity determination. Table 1 ) . Various concentrations of Fab 1 measurements were performed on a Biacore T100 at 37 uC. Fab 1 fragments, diluted in running buffer (HBS2EP1) and at a concentration range of 0.01-5.12 nM were injected for 350 s at a flow rate of 30 ml min
. The sensor surface was regenerated between each measurement with 20 mM NaOH. Binding affinity was determined by using the instrument software (Biacore T100 Evaluation software, v.2.0.3). Immunocytochemistry. For immunocytochemistry, organotypic slices were washed twice in PBS and fixed in 4% formalin overnight at 4 uC. Membrane inserts were washed and incubated for 1 h in blocking buffer (0.05% vol/vol Triton X-100 and 3% vol/vol goat serum dissolved in PBS) and incubated with conjugated mouse anti-NeuN-Alexa 488 (0.5 mg ml
, Millipore) antibody diluted in blocking buffer at 4 uC for 3 d. Inserts were washed four times with PBS and counterstained with 4,6-diamidino-2-phenylindole (DAPI) (1 mg ml
). For NeuN morphometry images were recorded at 34 magnification on a fluorescence microscope (BX-61, Olympus) equipped with a cooled black/white charge coupled device (CCD) camera at identical exposure times. The area of immunoreactivity was determined by morphometry with image analysis software analySIS v.5.0 using identical greyscale threshold settings for identifying positive pixels.
Mice were euthanized after the last scan (either 5, 24 or 72 h post injection) and brains fixed in 4% formalin. Cerebella were paraffin embedded and 2-mm coronal sections were cut and stained. Hematoxylin and eosin staining and NeuN immunohistochemistry were performed according to standard protocols. Proteolytic assays. Slices were collected in pools of 18 slices in PBS, 0.5% DOC, 0.5% NP-40 with 2% b-mercaptoethanol and homogenized by trituration. Homogenates were analysed immediately for DEVDase activity using caspase 3 fluorometric detection kit (Caspase-3 activity assay kit, Enzo Life Sciences) and normalized to protein concentration. Slices (pools of 18) were homogenized and processed according to the manufacturer's instructions (Calpain Activity Assay kit, Biovision). Calpain activity (Ac-LLY-ase) was measured by detecting cleavage of a specific fluorogenic calpain substrate, Ac-LLY-AFC on a fluorescence plate reader (360-nm excitation filter, 440-nm emission filter) and normalizing to protein amount. Electron microscopy. Slices were washed in Na-phosphate buffer, fixed in freshly prepared 2% PFA plus 2.5% glutaraldehydein 0.1 M Na-phosphate buffer 0.1 M pH 7.4, postfixed in 1% osmium tetroxide for 1-2 h, dehydrated through a series of graded ethanols and propylene oxide, embedded in Epon and processed for electron microscopy using standard procedures. Grids were examined and photographed in JEOL JEM 100 CX and JEOL JEM 1011 transmission electron microscopes at 80 kV. Nuclear morphology (as presented in Supplementary Fig. 10 ) was assigned by counting 11 fields for IgG-treated COCS at 3, 7 and 10 dpe. For POM1-treated COCS, 10 fields at 3 dpe, 12 fields at 5 and 10 dpe, were analysed. When defining necrotic, apoptotic and normal POM1-treated slices at 7 dpe, respectively 15, 16 and 20 fields were counted. Viability and ROS assays. For propidium iodide (PI) incorporation, slices were incubated for 30 min with PI (5 mg ml
) and images were recorded in living tissue using a fluorescent microscope (Axiovert 200) equipped with a cooled CCD camera using a 35 objective and analysed by morphometry. Lucigenin conversion assay was performed at room temperature as follows. Inserts containing 5-10 slices each were washed in PBS and collected in Krebs-Ringer solution supplemented with complete mini protease inhibitor cocktail (Roche). Samples were triturated with a 30G syringe and 50 ml of each sample was mixed with 175 ml assay buffer and 0.25 ml lucigenin (10 mM). Background activity was measured using a chemiluminescence reader. Subsequently, 50 ml NADPH (1 mM) was added to each well and the plate was read again. Background activity was subtracted from the NADPH dependent signal and data (each bar: average of 4 inserts 6 s. 21 buffer in a total volume of 125 ml. RBCs were incubated for 30 min at 37 uC, pelleted by centrifugation and 100 ml supernatant was transferred to a transparent 96-well plate and the absorbance at 414 nM was determined. Relative lytic activity was defined as the serum dilution factor leading to 30% erythrocyte lysis, calculated from the fitted serum dilution curves. Protein expression and isotopic labelling. ). The main culture was started by transferring cells from a 2 l preculture of LB medium grown to D 600 nm of 1.6 at 37 uC into 2 l of M9 D 2 O medium. Cells were further incubated for 1 h at 37 uC and induced by addition of 1 mM IPTG. After 6 h cells were collected and PrP was purified according to our standard protocol 29, 42 . NMR experiments. N-labelled PrP and in complex with scFv POM1 were performed on a Bruker Avance 700 MHz spectrometer equipped with a 5 mM triple-resonance cryoprobe and a single pulsed field gradient in 10 mM sodium phosphate, pH 7.3 and 5% (v/v) D 2 O at 20 uC. The data were processed by the software XwinNMR, version 3.5 (Bruker, Germany) and further analysed by the program CARA (http://www.nmr.ch) 44 . For the assignment of residues 89-230 the assignments deposited in the BioMagResBank (accession numbers: PrP(90-231), 16071; numeration corresponding human PrP) were used, whereas for residues 23-88 a tentative assignment was performed based on the available assignments at pH 4.5 (ref. 45) . Statistical analysis of COCS. One-way ANOVA with Tukey's post-hoc test for multi-column comparison, or Dunnett's post-hoc test for comparison of all columns to a control column, were used for statistical analysis of experiments involving the comparison of three or more samples. A paired Student's t-test was used for comparing the two samples. Results are displayed as the average of replicas 6 s.d. Statistical analysis of MEMRI data sets. For statistical analysis of experiments involving the comparison of three or more data sets, we used one-way ANOVA with Dunnett's post-hoc test for comparison of all data sets to a control data set. One or two-tailed unpaired Student's t-test was used for comparing two data sets. Results are displayed as mean 6 s.d. *P , 0.05; **P , 0.01; ***P , 0.001, ****P , 0.0001. Data collection and structure determination. Diffraction quality POM1 Fab 1 -PrP(120-230) protein complex crystals were grown by the vapour diffusion method at room temperature 46 . X-ray diffraction data were measured at the Stanford Synchrotron Radiation Laboratory (SSRL), beamline 9-2 (refs [47] [48] [49] . The data were processed in space group C2 to a resolution of 1.9 Å using the program HKL2000 (ref. 50) . The data collection details as well as the refinement statistics are presented RESEARCH LETTER
